Interstitial Lung Disease Treatment Guidelines

Interstitial Lung Disease Treatment Guidelines Aim to Relieve Patients’ Symptoms and Enhance Quality of Life

Various guidelines have been created for the treatment of interstitial lung disease, a group of conditions that cause the progressive scarring of lung tissue. As of this time, interstitial lung disease is incurable and the damage it causes cannot be reversed. Therefore, treatment generally is aimed at alleviating associated symptoms using a variety of methods, including the following:

  • Anti-fibrotic medications
  • Anti-inflammatory medications
  • Antibiotics
  • Immunosuppressive medications
  • Nutrition counseling
  • Pulmonary rehabilitation
  • Supplemental oxygen therapy

One of the objectives of interstitial lung disease management is to create a personalized course of treatment specific to a patient’s unique needs. At the Lung Institute, we work toward achieving this goal by offering two different types of cellular therapy. It is geared toward slowing disease progression and improving quality of life.

Our cellular therapy methods are performed in a clinical setting on an outpatient basis over the course of two days. Above all, our goal is to help our patients find a specialized plan of treatment that will allow them to breathe easier.

If you are living with interstitial lung disease, please contact the Lung Institute today at (800) 729-3065. We would be happy to provide you with additional information on interstitial lung disease treatment guidelines and help you determine whether cellular therapy may be a beneficial addition to your course of treatment.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.